The FAA is evaluating the use of each vaccine by medical certificate and medical clearance holders as soon as the U.S. Food and Drug Administration (FDA) issues an emergency use authorization (EUA). On Dec. 12, 2020, the day after the FDA issued the EUA for the first COVID-19 vaccine in the U.S., the FAA issued a policy statement approving pilots and air traffic controllers to receive the two-dose vaccine subject to a 48-hour waiting period after each dose before resuming sensitive-safety functions. Following the FDA's issuance of a second EUA, the FAA issued a similar policy statement for that vaccine.
The COVID-19 vaccine produced by Moderna requires two doses 28 days apart and is available to the American public under provisions of an Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA). After careful review of available data regarding safety profiles, the FAA Office of Aerospace Medicine (AAM) adopts the following policy as both safe and operationally responsive to this unique situation:
Holders of FAA-issued Airman Medical Certificates or Medical Clearances may receive the Moderna COVID-19 vaccine; however, a 48-hour “No Fly/No Safety-Related Duty” interval must be observed after each dose.
Individuals holding an Airman Medical Certificate or Medical Clearance should be reminded that they are prohibited from performing flight crewmember duties or air traffic control duties if they do not meet medical certification requirements, including those related to adverse events from medications that render them unable to perform such duties.
AAM will monitor the patient response to each vaccine dose and may adjust this policy as necessary to ensure aviation safety. Additional vaccines will each be evaluated as EUAs are issued.
12/12/2020
Use of COVID-19 Vaccines by Pilots and Air Traffic Controllers
The COVID-19 public health emergency has driven extraordinary global efforts to develop an effective and safe vaccine. Some of the vaccines in clinical testing are using novel technology, such as mRNA. The vaccine produced by Pfizer and BioNTech has been made available to the American public under an Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA).
After careful review of available data regarding safety profiles, the FAA Office of Aerospace Medicine (AAM) adopts the following policy as both safe and operationally responsive to this unique situation:
Holders of FAA-issued Airman Medical Certificates or Medical Clearances may receive the Pfizer-BioNTech COVID-19 vaccine; however, a 48-hour no fly/no safety related duty interval must be observed after each dose.
AAM will monitor the patient response to Pfizer-BioNTech vaccine and may adjust this policy as necessary to ensure aviation safety. Additional vaccines will each be evaluated as EUAs are issued.
Parnda Hedima is a Business, Aviation & Research Consultant who is a member of the National Business Aviation Association. Experimental Aircraft Association, & Aircraft Owners & Pilots Association.
For more information on how Business Aviation can support your Operations and Activities please contact us or call us on (239) 227-5768. We can facilitate your Business Aircraft Purchase.
Комментарии